Use of Electronic Monitoring Induces a 40-Day Intervention Effect in HIV Patients

Deschamps, Ann; Wijngaerden, Eric Van; Denhaerynck, Kris; Geest, Sabina De; Vandamme, Anne‐Mieke

doi:10.1097/01.qai.0000246034.86135.89

Cited by 49 publications

(57 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To mitigate the potential adherence-enhancing effect of patients using a MEMS device, we decided to assess medication compliance over a 10-week period. This approach is justified by studies that report waning of the adherenceenhancing effect after around 5 weeks (33,34) and by other research that suggests electronic monitors present no such effect at all (35). In contrast, certain researchers also believe that this waning effect is more prolonged (up to 6 months) (36).…”

Section: Discussionmentioning

confidence: 97%

Patients' Self-Reported Adherence to Cardiovascular Medication Using Electronic Monitors as Comparators

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Patients' Self-Reported Adherence to Cardiovascular Medication Using Electronic Monitors as Comparators

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Recently presented data suggest that electronic monitoring induces an improvement in adherence or "Hawthorne effect" that is self-limiting after 40 days, even among those participants that report no such effect (49). If these data are replicated in other populations, solutions to the "Hawthorne effect" may lie in study design (a phase in period to control for the 40 day effect) or data analysis (excluding the period of initial use).…”

Section: Electronic Drug Monitoringmentioning

confidence: 99%

Practical and Conceptual Challenges in Measuring Antiretroviral Adherence

Berg

Arnsten

2006

JAIDS Journal of Acquired Immune Deficiency Syndromes

260

264

View full text Add to dashboard Cite

Accurate measurement of antiretroviral adherence is essential for targeting and rigorously evaluating interventions to improve adherence and prevent viral resistance. Across diseases, medication adherence is an individual, complex, and dynamic human behavior that presents unique measurement challenges. Measurement of medication adherence is further complicated by the diversity of available measures, which have different utility in clinical and research settings. Limited understanding of how to optimize existing adherence measures has hindered progress in adherence research in both HIV and other diseases. Though self-report is the most widely used adherence measure and the most promising for use in clinical care and resource limited settings, adherence researchers have yet to develop evidence-based standards for self-reported adherence. In addition, the use of objective measures, such as electronic drug monitoring or pill counts, is limited by poor understanding of the source and magnitude of error biasing these measures. To address these limitations, research is needed to evaluate methods of combining information from different measures. The goals of this review are to describe the state of the science of adherence measurement, to discuss the advantages and disadvantages of common adherence measurement methods, and to recommend directions for improving antiretroviral adherence measurement in research and clinical care.

show abstract

“…Patients were informed about the function of the MEMS TM with a potential positive impact on the medication adherence [16]. On the other hand, it is known, that after 4 to 8 weeks, patients fall back into their conventional behaviour pattern [17,18]. As the observation period lasted 185 days on average, confounding effects at the beginning of the observation period should be equalized.…”

Section: Study Populationmentioning

confidence: 99%

A Comparative, Multicenter, Observational Study of Medication Adherence in Liver Cirrhosis Patients and Dialysis Patients Using Electronic Event Measurement

Heeb¹,

Greif-Higer²,

Lutz³

et al. 2017

J Pharma Care Health Sys

View full text Add to dashboard Cite

Introduction: Medication adherence was only studied in a limited number of potential organ recipients. So far medication adherence was not evaluated by utilizing electronic monitoring systems in dialysis and liver cirrhosis patients. The main objective of the present study was to measure the medication adherence of patients suffering from end stage kidney or liver disease by an objectified method. Methods:Adult liver cirrhosis patients taking propranolol and dialysis patients taking phosphate binders, each medication 3 times daily, were eligible to be enrolled in the study protocol. Medication adherence was measured electronically with MEMS TM -containers over a period of 6 months in each patient.Results: 34 patients suffering from liver cirrhosis and 36 dialysis patients participated in the study and were analysed per protocol. The Dosing Adherence (DA) rate differed significantly (p<0.023) between the two patient groups (mean DA rate of liver cirrhosis patients vs. dialysis patients: 61% vs. 43%). Conclusion:Low medication adherence rates observed in liver cirrhosis patients and dialysis patients ask for better patient education. Pharmaceutical care programs enhancing adherence should be implemented in both patient groups before transplantation and continued after transplantation.

show abstract

Use of Electronic Monitoring Induces a 40-Day Intervention Effect in HIV Patients

Cited by 49 publications

References 8 publications

Patients' Self-Reported Adherence to Cardiovascular Medication Using Electronic Monitors as Comparators

Patients' Self-Reported Adherence to Cardiovascular Medication Using Electronic Monitors as Comparators

Practical and Conceptual Challenges in Measuring Antiretroviral Adherence

A Comparative, Multicenter, Observational Study of Medication Adherence in Liver Cirrhosis Patients and Dialysis Patients Using Electronic Event Measurement

Contact Info

Product

Resources

About